Antibacterial Drug Development

For some start-ups, keeping pace with Big Pharma's shifting business priorities means following a path of less resistance. New companies are being formed around Big Pharma assets that no longer fit their priorities and market needs; others are fueled by novel discovery approaches based on elucidating and harnessing the power of natural genetic mechanisms.

Although the lack of development success is frustrating to physicians, patients, and payers, that only two new classes of antibiotics have been approved since 2000--the oxazolidone linezolid (Zyvox, from Pfizer Inc. ) and daptomycin (Cubicin, from Cubist Pharmaceuticals Inc. )—continues to be encouraging news to start-up companies. In some cases, new companies are being formed around Big Pharma assets that no longer fit their priorities and market needs: indeed, much of the focus of large-company antibacterial research remains the development of broad-spectrum agents against gram-positive bacteria such as methicillin-resistant Streptococcus aureus (MRSA) and streptococcal pneumonia. At the same time, the potentially large payoffs for success, in the form of collaboration dollars or acquisition, should keep deal values high even for successful niche players.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By 

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By 

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.